Viz.ai Appoints Dr. Timothy N. Showalter as First Chief Medical Officer

Accomplished AI and Oncology Leader to Drive Clinical Strategy and Product Expansion

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Tim Showalter, MD, MPH, MBA, as its first Chief Medical Officer (CMO). Dr. Showalter, an accomplished academic radiation oncologist, will lead Viz.ai’s clinical strategy and advance the company’s mission to use artificial intelligence to improve access to life-saving care. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai.

Dr. Showalter brings more than 15 years of leadership experience across oncology diagnostics, AI-driven health technology, and academic medicine. Most recently, he served as Chief Medical Officer at Artera AI, where he helped pioneer AI-based biomarkers for personalized oncology care, including the first digital pathology AI test to receive FDA clearance and recognition on national guidelines. He previously founded Advaray, Inc., a radiation therapy device company that developed and received FDA clearance for BrachyGel^TM, before being acquired by CQ Medical.

“Tim’s unique combination of clinical excellence, deep AI and oncology experience, and proven success in translating innovation into clinical impact make him the perfect clinician to deliver on the broad applicability of the Viz.ai Platform,” said Chris Mansi, MD, CEO and co-founder of Viz.ai. “As Viz expands its clinical footprint into oncology, pulmonology and other areas, Tim’s leadership will help ensure that our portfolio of products continues to deliver meaningful clinical and financial outcomes for patients, health systems and our life science partners.”

At Viz.ai, Dr. Showalter will oversee the design and implementation of AI-assisted care pathways and the company’s strategic partnerships with life sciences partners, leading health systems, and societies. His work will focus on expanding Viz.ai’s evidence generation and advancing real-world implementation of AI across new disease areas.

“I am honored to join Viz.ai at this inflection point for its growth,” said Dr. Showalter. “Viz has already redefined how AI can be combined with care coordination to accelerate patient care and improve outcomes for acute medical conditions. I look forward to building on that foundation to bring transformative, data-driven solutions to more diseases to improve the lives of patients worldwide who face complex conditions, and to better support the clinicians who serve them.”

Dr. Showalter is a Professor of Radiation Oncology at the University of Virginia School of Medicine, where he maintains a part-time clinical practice. He has co-authored nearly 200 peer-reviewed papers, led NIH-funded research, and was recognized as UVA’s Edlich-Henderson Innovator of the Year in 2023. He is a nationally-recognized cancer researcher and previously held leadership positions at the University of Virginia and Flatiron Health.

He holds an MD from the University of Virginia, an MPH from Johns Hopkins University, and an MBA from the University of Massachusetts Amherst.

About Viz.ai

Viz.ai is the leader in AI-powered care coordination and clinical workflow solutions, deployed in over 1,900 hospitals across the U.S and trusted by most of the top life sciences companies. Its platform uses artificial intelligence to detect diseases earlier, synchronize care teams, and ensure patients get to the right treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey, setting the standard for innovation in healthcare. For more information, visit Viz.ai.